Robbins Geller Rudman & Dowd LLP Files Securities Class Action Against Geron Corporation.
Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California against Geron Corporation (NASDAQ: GERN).
The lawsuit is brought on behalf of investors who purchased or otherwise acquired Geron securities between February 28, 2024, and February 25, 2025, inclusive (the “Class Period”). It seeks to recover damages for investors under the federal securities laws.
The case is captioned Dabestani v. Geron Corporation, No. 25-cv-02507, and is related to Potvin v. Geron Corporation, No. 25-cv-02563, also pending in the same court.
Investors who suffered significant losses during the Class Period have until May 12, 2025, to seek appointment as lead plaintiff. The lead plaintiff is a court-appointed representative who acts on behalf of other class members in directing the litigation.
To discuss your rights or eligibility, contact attorneys J.C. Sanchez or Jennifer N. Caringal at Robbins Geller Rudman & Dowd LLP by calling (800) 449-4900 or emailing [email protected].
Geron is a commercial-stage biopharmaceutical company focused on developing cancer therapies. Its leading product, Rytelo (imetelstat), is a telomerase inhibitor designed to treat certain types of blood cancer.
According to the complaint, Geron and several of its executives misled investors by overstating the commercial potential of Rytelo and underreporting known obstacles to its success.
The company allegedly gave investors an impression of strong market demand and growth prospects, while downplaying the impact of competition, lack of awareness, and the burdensome monitoring requirements associated with the drug.
These factors, the complaint states, significantly limited Rytelo’s market penetration, particularly among first-line patients and those treated outside academic settings.
What Prompted the Lawsuit
On February 26, 2025, Geron released its financial results for the fourth quarter of 2024, revealing that Rytelo’s growth had stagnated. In its announcement, the company cited seasonal demand issues, competition, low awareness, and the complexities of patient monitoring as key reasons for the disappointing performance.
Following this news, Geron’s stock price declined by more than 32%, resulting in steep losses for investors and prompting the filing of this class action.
Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Geron securities during the Class Period may seek appointment as lead plaintiff. While serving as lead plaintiff is not required to share in any potential recovery, it allows an investor to play an active role in the direction of the case.
If you invested in Geron Corporation (NASDAQ: GERN) during the Class Period and sustained financial losses, you may be eligible to join the lawsuit. The deadline to file a motion for lead plaintiff appointment is May 12, 2025.
To learn more or to submit your information:
Call Robbins Geller at (800) 449-4900
Email [email protected]
Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities class action litigation, shareholder derivative actions, and consumer protection cases. Established in 1992, the firm has earned a reputation for its expertise in handling complex legal matters on behalf of institutional investors, individuals, and consumer groups. With a team of skilled attorneys, Robbins Geller is known for its dedication to securing justice and maximizing recoveries for clients, often representing those who have suffered significant financial losses. The firm has a history of success in landmark cases, and its attorneys are recognized as leaders in the field of securities litigation. Robbins Geller operates nationwide and has offices in major U.S. cities.
More Articles from Lawyer Monthly